Award
National Cancer Institute 5R01CA262420-04
SLC6A14 as a unique drug target to treat pancreatic cancer
Recipient
Texas Tech University Health Sciences Center, Lubbock, TX
Award Amount
$349,640.00
Ceiling
$349,640.00
Awarded
April 10, 2026
Identifier
5R01CA262420-04
This award funds research to investigate SLC6A14 as a drug target for pancreatic cancer, focusing on mechanisms of tumor growth and testing combination therapies to improve treatment outcomes.
Description
The project aims to evaluate SLC6A14 as a drug target for pancreatic ductal adenocarcinoma (PDAC). It involves characterizing autophagy and macropinocytosis induced by SLC6A14 inactivation and testing combination therapies targeting SLC6A14 and autophagy/macropinocytosis to improve therapeutic outcomes.